PatternsRadar
Sign in

GLANDGland Pharma Limited

NSE
Full chart
3,006.10INR+94.60 (+3.25%)Close · 6 Oct 2026
10 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹49,604 CrMarket cap
43.9P/E (TTM)
64.6%Delivery

Filings & corporate actions

22 results filed
CSV
Next results · Q2 FY27
Expected 22 Oct 2026 – 6 Nov 2026
Estimate: filed 22–37 days after quarter end, last 5 times
Dividend
₹20.00 per share · last 11 Aug 2026
2026
  • 11 AugdividendDividend · ₹20.00 per share+9.6%
  • 10 AugresultsResults · Q1 FY27 · consolidated and standalone+9.6%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026+0.4%NSE
  • 15 MayresultsResults · Q4 FY26 · consolidated and standalone+15.4%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026+3.6%NSE
  • 28 JanresultsResults · Q3 FY26 · consolidated and standalone+6.5%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-2.8%NSE

Reaction to results · all yearsrose on day 0 in 11 of 22 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2710 Aug 2026+9.6%+7.2%+10.9%19.6×
Q4 FY2615 May 2026+15.4%+24.9%+16.6%48.0×
Q3 FY2628 Jan 2026+6.5%+11.8%+9.4%22.2×
Q2 FY263 Nov 2025-3.1%-6.8%-10.2%3.8×
Q1 FY265 Aug 2025-0.4%-0.7%-3.7%4.1×
Q4 FY2520 May 2025+4.9%+1.8%+15.8%7.5×
Q3 FY253 Feb 2025-3.7%-4.1%+4.1%3.8×
Q2 FY254 Nov 2024+13.8%+9.5%+13.9%32.7×
Q1 FY256 Aug 2024-3.8%-7.1%-10.2%5.1×
Q4 FY2422 May 2024+5.0%+3.2%+1.3%11.6×
Q3 FY2414 Feb 2024-2.7%-2.6%-10.3%5.5×
Q2 FY246 Nov 2023+5.0%+3.2%+12.3%6.3×
Q1 FY247 Aug 2023+20.0%+15.2%+26.0%7.4×
Q4 FY2319 May 2023-20.0%-30.2%-24.2%4.7×
Q3 FY2323 Jan 2023-1.5%-8.2%-3.6%4.7×
Q2 FY2326 Oct 2022-14.6%-17.1%-23.9%15.3×
Q4 FY2220 May 2022-1.1%-6.2%-17.2%0.8×
Q3 FY2221 Jan 2022-7.4%-1.5%-9.0%3.0×
Q2 FY2222 Oct 2021+0.9%-0.3%-5.0%6.5×
Q1 FY2221 Jul 2021+9.3%+5.4%+4.3%7.5×
Q4 FY2118 May 2021+9.6%+17.2%+12.6%4.3×
Q3 FY2122 Jan 2021-1.5%-8.1%+4.2%1.2×
Average+1.8%+0.3%+0.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+19.6%
Profit YoY+47.1%
Interest cost YoY-45.4%
Revenue QoQ+3.3%
Profit QoQ-13.6%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+7.1%+19.1%————
Profit+25.0%+14.8%————

Key data

CSV
Open2,921.10
Day range2,898.10 – 3,019.80
52-week range1,573.60 – 3,042.00
From 52w high-1.2%
RSI (14)59.7
ATR (14)88.06
Volume3.74L
Avg volume (20D)5.04L
Rel volume0.74×
Volatility (1Y)32.7%
Turnover₹112.4Cr
SMA 50 / 2002,826.91 / 2,160.82

Delivery percentage

Latest · 6 Oct 202664.6%
20-day avg55.9%
1-year avg53.9%
Percentile (own history)77th
Range8.5–94.7%
Sessions1,451

Over the last 20 sessions GLAND settled 55.9% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 53.9%. The latest session ranks higher than 77% of the 1,451 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+3.25%+3.80%+3.38%+17.89%+78.02%+53.52%

Valuation

CSV
Market cap₹49,604 Cr
P/E (TTM)43.9
EPS (TTM)68.41
Shares outstanding16.50Cr
Listed20 Nov 2020

Ownership

CSV
Promoter51.77%
Promoter Δ QoQ-0.06 pp
Public48.23%
FII8.74%
DII30.44%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)1,486.91,695.41,742.81,800.3
YoY chg+5.8%+22.5%+22.3%+19.6%
Net profit (₹ Cr)183.7261.5366.7317.0
YoY chg+12.3%+27.7%+96.6%+47.1%
Net margin12.4%15.4%21.0%17.6%
EPS11.1515.8722.2319.22

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 51.77% · public 48.23%
30 Sept 2021: promoter 58.02%31 Dec 2021: promoter 58.00%31 Mar 2022: promoter 58.00%30 Jun 2022: promoter 57.87%30 Sept 2022: promoter 57.86%31 Dec 2022: promoter 57.86%31 Mar 2023: promoter 57.86%30 Jun 2023: promoter 57.86%30 Sept 2023: promoter 57.86%31 Dec 2023: promoter 57.86%31 Mar 2024: promoter 57.86%30 Jun 2024: promoter 51.83%30 Sept 2024: promoter 51.83%31 Dec 2024: promoter 51.83%31 Mar 2025: promoter 51.83%30 Jun 2025: promoter 51.83%30 Sept 2025: promoter 51.83%31 Dec 2025: promoter 51.83%31 Mar 2026: promoter 51.83%30 Jun 2026: promoter 51.77%
2021-092026-06
  • Promoter
  • Public and others
Promoter
51.77%
Public
48.23%
Promoter change
-0.06 pp
Filed
20 Jul 2026
FII
8.74%
DII
30.44%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue from operations1,373.41,545.21,537.51,401.71,405.81,384.11,424.91,505.61,486.91,695.41,742.81,800.3
Other income53.237.442.151.459.758.544.057.584.263.2111.561.2
Total income1,426.61,582.51,579.61,453.11,465.51,442.51,468.91,563.11,571.01,758.51,854.31,861.5
Total expenses1,136.71,299.41,281.41,234.91,208.71,143.21,180.61,250.41,287.11,372.11,348.51,426.5
└ Finance costs6.05.310.05.66.122.87.511.57.83.910.04.4
└ Depreciation81.3105.392.692.093.896.395.8101.1106.3107.6108.7111.3
Profit before tax289.9283.2298.2218.2256.8299.3288.3312.7283.9362.1505.8435.0
Tax expense95.891.3105.874.593.294.6101.897.3100.2100.7139.1118.0
Net profit194.1191.9192.4143.8163.5204.7186.5215.5183.7261.5366.7317.0
EPS11.7811.6511.688.739.9312.4211.3213.0811.1515.8722.2619.23
Net margin14.13%12.42%12.52%10.26%11.63%14.79%13.09%14.31%12.35%15.42%21.04%17.61%
PBT margin21.11%18.33%19.40%15.57%18.27%21.63%20.24%20.77%19.09%21.36%29.02%24.16%
Tax rate33.05%32.24%35.48%34.13%36.31%31.61%35.30%31.10%35.30%27.79%27.51%27.13%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 10 Aug 2026.

GLAND at a glance

  • GLAND closed at ₹3,006.1 on 6 Oct 2026, +3.25% on the day, +53.5% over one year, 1.2% below its 52-week high of ₹3,042.
  • Delivery was 64.6% of traded quantity on 6 Oct 2026, the 77th percentile of its own 1,451 sessions with a reading (20-session average 55.9%, 1-year average 53.9%).
  • Market capitalisation is ₹49,604 crore at a trailing P/E of 43.9 (trailing EPS ₹68.41).
  • Q1 FY27 results (consolidated, filed 10 Aug 2026): revenue ₹1,800 crore (+19.6% year on year), net profit ₹317 crore (+47.1%); the price moved +9.6% on the first session after.
  • Promoters held 51.77% at 30 Jun 2026, down 0.06 percentage points on the previous filing.
  • Q2 FY27 results are expected between 22 Oct 2026 and 6 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE068V01023
SeriesEQ
Listed20 Nov 2020
History from20 Nov 2020
Sessions1,455
Turnover rank#209

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE